The Advisory Council on Alzheimer’s Research provided updates on Alzheimer Disease (AD) and AD and related dementias (ADRD) treatments and ongoing research in a virtual meeting. New treatments for AD, such as Leqembi and donanemab, were discussed. Biogen Inc. discontinued Aduhelm in favor of prioritizing lecanemab. Resources for dementia caregivers have increased, including a public health curriculum and initiatives to address diversity needs and caregiver wages. Funding for AD research has been extended and reauthorized, with increases in federal funding. Challenges in AD research include racial disparities, access to treatment, cost, and effectiveness of disease-modifying therapies. The connection between AD and Down syndrome was also highlighted, urging for more research in this area.
Source link
Advisory Council Releases Updates on Alzheimer Disease Treatments, Research
